The Company's marketing strength lies in a thorough market watch and study of health conditions the world over. By timely launch of new, technologically advanced molecules, Cadila’s strategic perceptions have consistently given the organization a distinct edge over the competition.

Today CPL’s products are available across the country, even in remote pockets, serviced by 25 C&S agents, 1900 wholesalers, 2, 37318 pharmacies and a field force of over 1,300 employees.

The Company's consistent efforts in brand building have resulted in Cadila Pharmaceuticals' being one of the most reputable names with the medical fraternity and among patients.
 

Cadila Brands

ENVAS

Cadila Pharmaceuticals makes India's No.1 ACE inhibitor, Envas, which has been listed among the country's top 50 Pharma Brands, across all categories.
Other CPL brands in top 300 brands of Indian Pharmaceutical Industry are Aciloc and Haem-Up.

ACILOC

A Ranitidine preparation, Aciloc is one of India's best selling brands in this category.

LMX, SYMBIOTIK, CLAX

Antibiotics with live Lactobacilli combination, LMX, SYMBIOTIK, CLAX are the first brands of its kind in India, for which Cadila Pharmaceuticals has applied for a worldwide patent. This unique innovation has already been granted Indian, UK and US, Eurasian & Sri Lankan patents.

RABELOC, ACILOC RD, ZASO, MIXULIN, MONTELAST AND NODON are some of the best selling brands in their categories.

CPL is the first company in India to introduce RABEPRAZOLE and FOSINOPRIL formulations.
 

DIABETOLOGY

CPL has a dedicated Diabetology Portfolio.

Named “Pharma Diabetology” with the theme “Sweetness of Living”, this cell offers primarily a basic product basket comprising Oral antidiabetics, viz. Sulphonylureas, Biguanides, Combination drugs and Insulins.

CPL has already entered into a technology transfer agreement for Insulin with M/S. Polfa Tarchomin, Poland. Polfa markets insulins since 1924 and offers Insulins in various Pharmacokinetic forms such as Chromatographically Purified and Highly Purified preparations.

CPL intends to create a distinct identity in the Indian Diabetic care market by promoting the theme of “Sweetness of Living” through unique customer friendly promotional strategies.
 

Le Sante

• A wide spectrum of Anti-TB drugs

• Anti-Allergics

• Anti-retrovirals

• Respiratory & Allied Products

• Pediatric Drugs

• Ophthalmology Drugs

• Anti-Migraine

• NSAIDs

• Cardiovascular Drugs

• Anti-Peptic Ulcerants

• Respiratory Drugs

• Anxyolytics

• Bone Supplements

• Prokinetic

• Cough & Cold

• Anti-infectives

• Anti-Hypertensives/Anti-anginals

• Anti-Ulcerants

• Anti-Anaemic

• Anti-Bacterials

• Anti-Peptic Ulcerants

• Vaccines & Sera

• Psychiatry

• Anti-Diabetics

• ED Drugs

• Antibiotics

• Pain Management

• Anti-Oxidants

• Lifetime Contribution Award for Mr. I. A. Modi, Chairman of CPL
• GCCI award for Mr. I.A. Modi
• Cadila Pharma Set To Tap The Rheumatology Segment
• Cadila to set up Rs. 45-cr facility in J&K